North & South America

North & South America

Argentina

Local distributor

Argentina

Canada
EN | FR
Colombia

Local distributor

Colombia

Perù

Local distributor

Perù

Uruguay

Local distributor

Uruguay

Venezuela

Local distributor

Venezuela

Europe

Europa

Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

Bulgaria

Local distributor

Bulgaria

Croatia

Local distributor

Croatia

Greece

Local distributor

Greece

Hungary

Local distributor

Ungheria

Malta

Local distributor

Malta

Romania

Local distributor

Romania

Serbia

Local distributor

Serbia

Slovenia

Local distributor

Slovenia

Eastern Europe, Middle East & Africa

Eastern Europe, Middle East & Africa

Estonia

Local distributor

Estonia

Ethiopia

Local distributor

Ethiopia

Ghana

Local distributor

Ghana

Israel

Local distributor

Israel

Jordan

Local distributor

Jordan

Kenya

Local distributor

Kenya

Lebanon

Local distributor

Lebanon

Latvia

Local distributor

Latvia

Lithuania

Local distributor

Lithuania

Mauritius

Local distributor

Mauritius

Russia

Local distributor

Russia

Saudi Arabia

Local distributor

Saudi Arabia

South Africa

Local distributor

South Africa

Uganda

Local distributor

Uganda

United Arab Emirates

Local distributor

United Arab Emirates

Asia Pacific

Asia Pacific

Australia

Local distributor

Australia

Taiwan - China

Local distributor

Taiwan - China

India

Local distributor

India

Indonesia

Local distributor

Indonesia

New Zealand

Local distributor

New Zealand

Pakistan

Local distributor

Pakistan

Philippines

Local distributor

Philippines

Singapore

Local distributor

Singapore

Thailand

Local distributor

Thailand

Vietnam

Local distributor

Vietnam

 

Select your country

Asia

Australia

Local distributor

Australia

India

Local distributor

India

Indonesia

Local distributor

Indonesia

New Zealand

Local distributor

New Zealand

Pakistan

Local distributor

Pakistan

Philippines

Local distributor

Philippines

Singapore

Local distributor

Singapore

Thailand

Local distributor

Thailand

Vietnam

Local distributor

Vietnam

North & South America

Argentina

Local distributor

Argentina

Colombia

Local distributor

Colombia

Perù

Local distributor

Perù

Uruguay

Local distributor

Uruguay

Venezuela

Local distributor

Venezuela

Europe

Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

Bulgaria

Local distributor

Bulgaria

Croatia

Local distributor

Croatia

Greece

Local distributor

Greece

Romania

Local distributor

Romania

Serbia

Local distributor

Serbia

Slovenia

Local distributor

Slovenia

Ungheria

Local distributor

Ungheria

Eastern Europe, Middle East & Africa

Ethiopia

Local distributor

Ethiopia

Ghana

Local distributor

Ghana

Israel

Local distributor

Israel

Jordan

Local distributor

Jordan

Kenya

Local distributor

Kenya

Lebanon

Local distributor

Lebanon

Mauritius

Local distributor

Mauritius

Saudi Arabia

Local distributor

Saudi Arabia

South Africa

Local distributor

South Africa

Uganda

Local distributor

Uganda

Ukraine

Local distributor

Ukraine

GLOBAL

Gadopiclenol: another milestone achieved

Milan , 30/03/2022

Bracco is very excited about the Priority Review granted by the U.S. Food and Drug Administration (FDA) to the New Drug Application (NDA) of the investigational high-relaxivity, macrocyclic gadolinium-based contrast agent (GBCA) Gadopiclenol, which follows the acceptance of the Marketing Authorization Application (MAA) made by Guerbet for the product in the European Union, as well as a duplicate MAA by Bracco.


A Priority Review designation means that FDA will take action months earlier compared with standard applications, and is a recognition by the U.S. Agency about the possible improvements in safety and/or effectiveness that Gadopiclenol, if approved, could provide to patients and to MRI healthcare professionals” says Fulvio Renoldi Bracco, Vice-Chairman of the Board & CEO of Bracco Imaging, a world leader in diagnostic imaging. ”It is a very important milestone in the collaboration between Guerbet and Bracco to bring this new MR agent to clinical fruition in the earliest possible time.”


Bracco Imaging and Guerbet have a worldwide collaboration on Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA). The two companies will be marketing the product independently under different brand names, while also collaborating on manufacturing, as well as research and development programs and activities to obtain regulatory approvals.
Bracco is looking forward to celebrating in June its 95th anniversary, a major milestone for a company that has constantly brought innovation to the market and will continue to do so with breakthrough products. Bracco's mission has always been innovation-driven, confirming its commitment to strengthening a leadership position in the diagnostic imaging space.


Gadopiclenol
Gadopiclenol is an investigational macrocyclic GBCA with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System and MRI of the head and neck, thorax, breast, abdomen, pelvis, musculoskeletal system. No Regulatory Authority has completed evaluation of the nonclinical and clinical data deriving from the development of the product. Both Guerbet and Bracco Imaging own valuable intellectual property relating to Gadopiclenol.